NVV1 Stock Overview
A biotechnology company, that promotes improved health by discovering, developing, and commercializing vaccines to protect against serious infectious diseases.
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 3/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
Novavax, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$14.84 |
| 52 Week High | US$15.70 |
| 52 Week Low | US$12.73 |
| Beta | 1.97 |
| 11 Month Change | n/a |
| 3 Month Change | n/a |
| 1 Year Change | n/a |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -76.95% |
Recent News & Updates
No updates
Recent updates
No updates
Shareholder Returns
| NVV1 | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 2.4% | -1.0% | -0.7% |
| 1Y | n/a | -19.5% | 1.4% |
Return vs Industry: Insufficient data to determine how NVV1 performed against the German Biotechs industry.
Return vs Market: Insufficient data to determine how NVV1 performed against the German Market.
Price Volatility
| NVV1 volatility | |
|---|---|
| NVV1 Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 6.1% |
| Market Average Movement | 4.6% |
| 10% most volatile stocks in DE Market | 10.1% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: NVV1 has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine NVV1's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1987 | 1,543 | John Jacobs | www.novavax.com |
Novavax, Inc., a biotechnology company, that promotes improved health by discovering, developing, and commercializing vaccines to protect against serious infectious diseases. It offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response. It focuses on urgent health challenges, which is evaluating vaccines for COVID-19, influenza, and COVID-19 influenza combination.
Novavax, Inc. Fundamentals Summary
| NVV1 fundamental statistics | |
|---|---|
| Market cap | €2.12b |
| Earnings (TTM) | -€367.89m |
| Revenue (TTM) | €919.57m |
2.2x
P/S Ratio-5.4x
P/E RatioIs NVV1 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| NVV1 income statement (TTM) | |
|---|---|
| Revenue | US$996.61m |
| Cost of Revenue | US$947.57m |
| Gross Profit | US$49.04m |
| Other Expenses | US$447.75m |
| Earnings | -US$398.71m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -2.84 |
| Gross Margin | 4.92% |
| Net Profit Margin | -40.01% |
| Debt/Equity Ratio | -19.4% |
How did NVV1 perform over the long term?
See historical performance and comparison